# Precigen Inc. (PGEN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.25, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Precigen Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 194.1×**. Each dollar of revenue is priced at 194.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 43.0×**. The shares trade at 43.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -6.1%** (5-yr avg -17.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on invested capital: -131.8%**. Return on all capital, debt included, is -131.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -161.2%**. Each dollar of assets produces -161.2% of profit.

## Growth
- **Revenue growth (1 yr): 146.7%** (3-yr -28.9%/yr, 5-yr -21.3%/yr). Revenue grew 146.7% over the last year, against -21.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -191.5%**. Earnings per share fell 191.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 4.46**. Debt is 4.46 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Precigen Inc. holds more cash than debt.
- **Interest coverage: -28.6×**. Operating profit covers interest only -28.6×: fragile.
- **Current ratio: 3.09** (quick 3.09). Current assets cover the next year's liabilities 3.09 times.
- **Altman Z-score: 6.89**. A Z-score of 6.89 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Precigen Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (3 analysts). 3 analysts cover Precigen Inc.; the consensus is buy, with an average price target of $13.65 (+160% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 24.2%** (YTD 23.0%, 3-mo -22.2%). The shares are up 24.2% over twelve months including dividends.
- **From 52-week high: -41.5%** (72.7% above the low). Trading 42% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 1.36** (volatility 83%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PGEN · Page: https://foliofundamentals.com/stocks/pgen

Not investment advice.